''
WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today reported financial results for the three and nine month periods ended September 30, 2016.
“While our revenue for the quarter was limited, I am very pleased with our solid operational progress”
Recent Highlights and Accomplishments
- Realized revenue of $688,000 in the third quarter of 2016, primarily from CorPath® System revenue as well as cassette, accessory and service revenue
- Installed one new CorPath System in the third quarter of 2016 increasing the total installed base to 41 CorPath Systems
- Received 510(k) clearance from the FDA for CorPath GRX, the second generation CorPath System
-
Established collaboration with ACIST Medical Systems to integrate
advanced technologies for PCI
- Robotic therapy incorporating Fractional Flow Reserve (FFR) and automated contrast delivery may provide workflow solutions to potentially improve clinical outcomes and enhance patient care
- Approximately 100 attendees at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 annual meeting participated in the breakfast symposium, “Robotic Therapy: Current Applications and Future Vision” chaired by Dr. Martin Leon of New York Presbyterian Hospital
-
Rounded out new leadership team with two key additions
- Appointed Jeff Lemaster as Chief Commercial Officer
- Appointed Suzette Jaskie as Vice President Global Medical Affairs
“While our revenue for the quarter was limited, I am very pleased with our solid operational progress,” said Mark Toland, President and Chief Executive Officer of Corindus. “We have made important investments in new talent, and now have a solid leadership team in place as we enter the new year.”
